http://stroke.ahajournals.org/cgi/content/full/37/4/1087Minocycline Improves Neurological Outcome and Reduces BBB Disruption, Hemorrhage, and Perivascular Microglial Accumulation In Vivo
http://www.medscape.com/viewarticle/459968_5A second agent that acts at the BBB is minocycline. Matrix metalloproteinases (MMPs) are produced during inflammation and contribute to the degradation of the basement membrane. This step is necessary for transmigration of activated T lymphocytes across the BBB and profoundly inhibited by one of the approved therapies, IFN-. Minocycline has been shown to inhibit the activity of MMPs and decrease production of MMP-9. In an EAE model, minocycline-treated animals had significantly attenuated disease. A current phase II trial of minocycline in relapsing-remitting MS patients is underway.
I would of posted this under antibiotics, but its not the antibiotic effect of mino that is important here.